Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Oas2em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Oas2em1flox/Cya

Common Name
Oas2-flox
Product ID
S-CKO-08745
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-246728-Oas2-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Oas2-flox Mouse (Catalog S-CKO-08745) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Oas2-flox
Strain ID
CKOCMP-246728-Oas2-B6J-VA
Gene Name
Oas2
Product ID
S-CKO-08745
Gene Alias
Oasl11
Background
C57BL/6JCya
Gene Full Name
2'-5' oligoadenylate synthetase 2
Modification
Conditional knockout
NCBI ID
246728 (Mouse)
Phenotype
MGI:2180852
Chromosome
Chr 5 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000081491
NCBI Transcript ID
NM_001347448.1
Target Region
Exon 2
Size of Effective Region
~1.1 kb
Overview of Gene Research
Oas2, a member of the 2'-5'-oligoadenylate synthetases (OAS) family, is an interferon (IFN)-induced antiviral enzyme [1,2,3,4,6,7,8,9]. It generates 2'-5'-linked oligoadenylates upon activation by double-stranded RNA, which can activate ribonuclease L to degrade single-stranded RNA. This process is involved in the antiviral response system and can also influence the IFN-activated Jak/STAT signaling pathway [3,7].

In breast cancer, high mRNA expression of Oas2 is associated with favorable prognosis, while in psoriasis, its overexpression is found in lesional skin and serum, and it contributes to epidermal keratinocyte proliferation by regulating the cell cycle and augmenting IFN-1-induced phosphorylation of Jak1 and signal transducer and activator of transcription 1 [1,2]. Inborn errors of Oas2 in children are related to SARS-CoV-2-related multisystem inflammatory syndrome (MIS-C), where Oas2-deficient monocytic cell lines produce excessive inflammatory cytokines upon dsRNA or SARS-CoV-2 stimulation [3]. Activation of Oas2 in a mouse model with an activating mutation prevented pregnancy-driven mammary cancer metastases and enhanced the effectiveness of checkpoint immunotherapy [4]. In testicular cancer, upregulating Oas2 by piR-36249 and DHX36 inhibits cancer cell progression [5]. Oas2 also restricts intracellular Mycobacterium tuberculosis replication, enhances pro-inflammatory cytokine secretion, and inhibits Zika virus replication through activation of the type Ι IFN signaling pathway [6,7]. In COVID-19, genetic variants in the gene cluster encoding Oas2 are associated with critical illness [8]. The activity of Oas2 is affected by the characteristics of double-stranded RNA, with a minimum dsRNA length requirement of 35 bp for activation [9]. In psoriasis, Oas2 is a potential biomarker for disease activity [10].

In conclusion, Oas2 plays crucial roles in multiple biological processes and disease conditions. Its functions range from antiviral responses to influencing cell proliferation, metastasis, and inflammation in various diseases such as cancer, psoriasis, and COVID-19. Studies using genetic models, especially in mice, have provided valuable insights into these functions, helping to understand the underlying mechanisms and potentially guiding the development of therapeutic strategies.

References:
1. Zhang, Yujie, Yu, Chaoran. 2020. Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer. In BMC cancer, 20, 575. doi:10.1186/s12885-020-07034-6. https://pubmed.ncbi.nlm.nih.gov/32560641/
2. Huang, Yan-Zhou, Zheng, Yu-Xin, Zhou, Yuan, Zheng, Min, Man, Xiao-Yong. 2022. OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis. In The Journal of investigative dermatology, 142, 2635-2645.e9. doi:10.1016/j.jid.2022.02.018. https://pubmed.ncbi.nlm.nih.gov/35305973/
3. Lee, Danyel, Le Pen, Jérémie, Yatim, Ahmad, Zhang, Shen-Ying, Casanova, Jean-Laurent. 2023. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. In Science (New York, N.Y.), 379, eabo3627. doi:10.1126/science.abo3627. https://pubmed.ncbi.nlm.nih.gov/36538032/
4. Ho, Wing-Hong Jonathan, Law, Andrew M K, Masle-Farquhar, Etienne, Oakes, Samantha R, Ormandy, Christopher J. 2022. Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases. In Breast cancer research : BCR, 24, 31. doi:10.1186/s13058-022-01525-z. https://pubmed.ncbi.nlm.nih.gov/35505346/
5. Wang, Qianqian, Chen, Peize, Wang, Xiaorong, Song, Xiaoyuan, Sun, Fei. 2023. piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2. In Non-coding RNA research, 8, 174-186. doi:10.1016/j.ncrna.2022.12.004. https://pubmed.ncbi.nlm.nih.gov/36710986/
6. Leisching, Gina, Cole, Victoria, Ali, Aus T, Baker, Bienyameen. 2019. OAS1, OAS2 and OAS3 restrict intracellular M. tb replication and enhance cytokine secretion. In International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 80S, S77-S84. doi:10.1016/j.ijid.2019.02.029. https://pubmed.ncbi.nlm.nih.gov/30822544/
7. Liao, Xinzhong, Xie, He, Li, Shilin, Yang, Chunhui, Chen, Limin. 2020. 2', 5'-Oligoadenylate Synthetase 2 (OAS2) Inhibits Zika Virus Replication through Activation of Type Ι IFN Signaling Pathway. In Viruses, 12, . doi:10.3390/v12040418. https://pubmed.ncbi.nlm.nih.gov/32276512/
8. Pairo-Castineira, Erola, Clohisey, Sara, Klaric, Lucija, Wilson, James F, Baillie, J Kenneth. 2020. Genetic mechanisms of critical illness in COVID-19. In Nature, 591, 92-98. doi:10.1038/s41586-020-03065-y. https://pubmed.ncbi.nlm.nih.gov/33307546/
9. Koul, Amit, Deo, Soumya, Booy, Evan P, Genung, Matthew, McKenna, Sean A. 2019. Impact of double-stranded RNA characteristics on the activation of human 2'-5'-oligoadenylate synthetase 2 (OAS2). In Biochemistry and cell biology = Biochimie et biologie cellulaire, 98, 70-82. doi:10.1139/bcb-2019-0060. https://pubmed.ncbi.nlm.nih.gov/30965010/
10. Zhou, Yuan, Wang, Ping, Yan, Bing-Xi, Zheng, Min, Man, Xiao-Yong. 2020. Quantitative Proteomic Profile of Psoriatic Epidermis Identifies OAS2 as a Novel Biomarker for Disease Activity. In Frontiers in immunology, 11, 1432. doi:10.3389/fimmu.2020.01432. https://pubmed.ncbi.nlm.nih.gov/32849499/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research